Table 3.
Treatment administration
| All patients | Phase 2 dose | |
|---|---|---|
| (N = 48) | (N = 45) | |
| Ixazomib | ||
| Number of cycles | 620 | 561 |
| Median dose (mg, Range) | 12 (3–120) | 12 (3–120) |
| Number of patients with dose reductions | 6 (13%) | 6 (13%) |
| Total number of dose reductions | 8 | 8 |
| Cyclophosphamide | ||
| Number of cycles | 382 | 357 |
| Median dose (mg, Range) | 2800 (0–5000) | 3000 (0–5000) |
| Number of patients with dose reductions | 16 (33%) | 16 (36%) |
| Total number of dose reductions | 24 | 24 |
| Dexamethasone | ||
| Number of cycles | 386 | 361 |
| Median dose (mg, range) | 160 (0–160) | 160 (0–160) |
| Number of patients with dose reductions | 20 (42%) | 18 (40%) |
| Total number of dose reductions | 29 | 26 |
| Treatment delays | ||
| Number of patients | 14 (25%) | 12 (27%) |
| Total number of delays | 19 | 15 |